GH1 and metabolic dysfunction-associated steatotic liver disease: This is, in part, because somatotropic-liver axis is a main regulator of intrahepatic lipid content, where GH and IGF1 are potential disease modifiers in the development and progression of lipid metabolism associated disorders such as nonalcoholic fatty liver disease (NAFLD) (24).